Evidence map›Paper›PMID 40627032›Full record

ReviewMolecular biology reports2025

MicroRNA-451: A multifaceted regulator in cerebral and cardiac ischemia-reperfusion injury - from molecular mechanisms to therapeutic potential.

Fei-Xiang Wang, Zu-An Shi, Zi-Hang Yu, Bin Lu, Guo Mu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fei-Xiang WangDepartment of Anesthesiology, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Zu-An ShiDepartment of Anesthesiology, The Second Clinical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, 637000, Sichuan, China.
Zi-Hang YuDepartment of Anesthesiology, Fushun County People's Hospital, Zigong, 643200, Sichuan, China.
Bin LuDepartment of Anesthesiology, Zigong Fourth People's Hospital, Zigong, 643000, Sichuan, China.
Guo MuDepartment of Anesthesiology, Zigong Fourth People's Hospital, Zigong, 643000, Sichuan, China. muguo@zg120.cn.

Funding

Sichuan Provincial Science and Technology Support Program MZGC20240086
6 · The paper itself

Abstract

Ischemia-reperfusion injury (IRI) represents a major clinical challenge across various organ systems, with especially severe and often irreversible consequences in cardiac and cerebral tissues. Despite advances in understanding its pathophysiology, effective therapeutic strategies remain limited. MicroRNA-451 (miR-451), a highly conserved non-coding RNA located on human chromosome 17q11.2, has emerged as a critical regulator of key pathophysiological processes underlying IRI, including inflammation, immune cell function, oxidative stress, and programmed cell death. This review comprehensively examines the complex and sometimes paradoxical roles of miR-451 in cardiac and cerebral IRI. We explore miR-451's potential as both a diagnostic biomarker and therapeutic target in IRI management, highlighting innovative approaches such as exosome-mediated miR-451 delivery. Finally, we address critical challenges in translating miR-451-based therapies to clinical practice and outline promising directions for future research. This comprehensive analysis provides a theoretical framework for developing novel miR-451-focused strategies for IRI detection and treatment, with significant implications for improving outcomes in ischemic disorders.

Indexed as

Brain IschemiaMicroRNAsMyocardial Reperfusion InjuryReperfusion InjuryAnimalsBiomarkersHumansOxidative StressBiomarkersMicroRNAsMIRN451 microRNA, humanBiomarkerCerebral injuryIschemia-reperfusion injuryMicroRNAsMiR-451

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.